PharmaEssentia Corporation Stock Deutsche Boerse AG
Stocks
8Z1
US7169722037
Biotechnology & Medical Research
|
Delayed
Deutsche Boerse AG
15:34:57 09/03/2026 HKT
|
5-day change | 1st Jan Change | ||
| 15.50 EUR | -.--% |
|
+11.00% | - |
| 08-31 | PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10% | MT |
| 08-29 | US FDA approves Takeda, Protagonist's drug for rare blood cancer | RE |
| Market Cap | 559B 17.63B 15.17B 14.24B 13.03B 24.31B 1,667B 24.5B 168B 65.59B 852B 66.22B 64.77B 2,743B | P/E 2026 * |
50.9x | P/E 2027 * | 32x |
|---|---|---|---|---|---|
| Enterprise Value | 533B 16.8B 14.45B 13.56B 12.41B 23.16B 1,588B 23.34B 160B 62.48B 811B 63.08B 61.7B 2,613B | EV / Sales 2026 * |
18.8x | EV / Sales 2027 * | 13.1x |
| Free-Float |
77.98% | Yield 2026 * |
0.3% | Yield 2027 * | 0.17% |
| 1 week | +11.00% | ||
| Current month | +11.00% | ||
| 1 month | +11.00% | ||
| 3 months | +11.00% | ||
| 6 months | +11.00% |
| Current year | 13.96 |  | 15.5 |
| 1 year | 13.96 | | 15.5 |
| 3 years | 13.96 | | 15.5 |
| 5 years | 13.96 | | 15.5 |
| 10 years | 13.96 | | 15.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kuo Chung Lin
CEO | Chief Executive Officer | - | 01/01/2017 |
Hsueh Ling Chang
DFI | Director of Finance/CFO | - | 14/10/2015 |
Cheng Ku Huang
PSD | President | - | 25/06/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Kuo Chung Lin
BRD | Director/Board Member | - | 09/05/2000 |
Ching-Leou Teng
CHM | Chairman | - | 24/09/2012 |
Cheng Ku Huang
BRD | Director/Board Member | - | 29/05/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +11.00% | - | - | 17.03B | |
| +1.03% | -2.05% | +39.28% | +94.60% | 68.87B | |
| +1.31% | +1.65% | +50.56% | +90.80% | 65.29B | |
| +0.13% | +3.28% | -12.63% | +375.45% | 27.65B | |
| +2.97% | -0.10% | +41.86% | +14.84% | 25.77B | |
| -1.04% | -7.90% | +2.17% | -15.91% | 26.08B | |
| +1.01% | +1.38% | +26.48% | -17.50% | 20.14B | |
| +3.45% | -14.83% | +225.22% | +389.50% | 17.03B | |
| +0.77% | -4.55% | -0.36% | +549.41% | 15.03B | |
| +0.96% | +7.08% | +60.11% | +165.72% | 14.5B | |
| Average | +0.98% | -2.66% | +48.07% | +182.99% | 31.15B | |
| Weighted average by Cap. | +1.00% | -2.12% | +42.90% | +141.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.33B 893M 768M 721M 660M 1.23B 84.4B 1.24B 8.53B 3.32B 43.13B 3.35B 3.28B 139B | 40.06B 1.26B 1.09B 1.02B 933M 1.74B 119B 1.75B 12.06B 4.7B 60.99B 4.74B 4.64B 196B |
| Net income | 11.02B 347M 299M 280M 257M 479M 32.84B 483M 3.32B 1.29B 16.78B 1.3B 1.28B 54.05B | 17.69B 558M 480M 450M 412M 769M 52.71B 775M 5.33B 2.07B 26.93B 2.09B 2.05B 86.75B |
| Net Debt | -26.52B -836M -719M -675M -618M -1.15B -79.02B -1.16B -7.98B -3.11B -40.38B -3.14B -3.07B -130B | -34.73B -1.09B -942M -884M -809M -1.51B -103B -1.52B -10.45B -4.07B -52.87B -4.11B -4.02B -170B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 6446 Stock
- 8Z1 Stock
Select your edition
All financial news and data tailored to specific country editions
